Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Neuroblastoma 5Prostatic Neoplasms 3Skin Neoplasms 2Precancerous Conditions 2Uterine Cervical Neoplasms 1Uterine Cervical Dysplasia 1Stomach Neoplasms 1Sarcoma, Ewing 1Osteosarcoma 1Non-melanoma Skin Cancer 1Neoplasms 1Medulloblastoma 1Keratosis, Actinic 1Gastritis, Atrophic 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Basal Cell 1Adenomatous Polyps 1Adenomatous Polyposis Coli 1

Interventions

Sulindac 2Specimen Handling 2Sirolimus 2Erlotinib Hydrochloride 2Endoscopy, Gastrointestinal 2Curcumin 2Celecoxib 2Biopsy 2obeticholic acid 1Surveys and Questionnaires 1Probiotics 1Pharmaceutical Preparations 1Niclosamide 1Metformin 1Lithium Carbonate 1Inulin 1Gastroscopy 1Endoscopy, Digestive System 1Eflornithine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Adenomatous Polyposis Coli × Eflornithine × Clear all
NCT00033371 2020-09-29

Celecoxib With or Without Eflornithine in Preventing Colorectal Cancer in Patients With Familial Adenomatous Polyposis

National Cancer Institute (NCI)

Phase 2 Completed
205 enrolled 16 charts
Gastrointestinal

Adenomatous Polyposis Coli, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡